StockMarketWire.com - ANGLE , a world-leading liquid biopsy company, has announced positive headline results from 400 patient pelvic mass studies, in the US and Europe.

It said the results demonstrated the potential for a Parsortix based blood test to out-perform current tests in discriminating between benign and malignant pelvic masses. Evaluation of data from both ANGLE's European study (ANG-001) led by Dr Robert Zeillinger at the Medical University of Vienna and ANGLE's US study (ANG-003) led by Dr Richard Moore at the University of Rochester Medical Center, Wilmot Cancer Institute (New York State) showed that a test using the Parsortix system can differentiate between women with a malignant pelvic mass and those with benign tumours with a high degree of sensitivity (correctly identifying cancer) of up to 95% whilst at the same time achieving a higher specificity (low false positive rate) than existing tests.

The Parsortix test combines both high sensitivity and high specificity. Compared to CA125 for the ANG-003 samples, at a high sensitivity the Parsortix result had nearly double the specificity of the CA125 result.




Story provided by StockMarketWire.com